7月 2026
- 首頁
- TISSIUM S.A.
7月 2026TISSIUM S.A.的市場佔有率分析
ALPHA Study of TISSIUM’s ECLIPSIUMTM System Is Underway in Belgium Paris, France, Boston, USA, September 12, 2023 – TISSIUM, a privately-owned medical technology company developing biomorphic programmable polymers for atraumatic...
TISSIUM S.A.(包含公司地區)
查看更多網站流量與參與度資訊- tissium.com
TISSIUM S.A.截至 7月 2026 的總收入為 25M - 50M
TISSIUM S.A. 熱門網域產生的總收入
TISSIUM S.A. 熱門網域 3 年內的總收入
TISSIUM S.A. 熱門網域的總收入
TISSIUM S.A.的熱門網域總造訪量
了解TISSIUM S.A.市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
TISSIUM S.A.的熱門網域平均造訪時長
分析TISSIUM S.A.參與度指標。
過去 3 個月平均造訪時長
子公司細目
TISSIUM S.A.的熱門網域平均頁面瀏覽量
了解TISSIUM S.A.如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自TISSIUM S.A.
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Tissium SA received financing of $57.7M in Series D on Jul 31st '26.If the medtech Tissium is somewhat behind in obtaining the marketing authorizations it had anticipated during its €50 million Series D round in (...)
7月 31, 2026閱讀更多
新聞Tissium received financing of $34.3M in Series D2 on Dec 31st '25.Paris, France, Cambridge, USA, June 24, 2026 - TISSIUM, a medical technology company pioneering biomorphic programmable polymers for tissue reconstruction, today announced a €60 million financing package combining a completed €30 million Series D2 financing with a €30 million financing facility from the European Investment Bank (EIB).
6月 24, 2026閱讀更多
新聞Tissium SA identified as competitor of BioCircuit Technologies.Tissium debuts its entirely atraumatic solution with a potential competitive advantage against other players in the nerve repair space, such as BioCircuit's Nerve Tape, which brings nerves together via miniature hooks.
6月 24, 2026閱讀更多
查看所有TISSIUM S.A.信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
